Events

Sierra Oncology (SRRA) Myelofibrosis KOL Panel to Highlight Momelotinib Data Presented at ASCO and EHA

June 23, 2021

The webinar will feature a presentation by Sierra’s management team to discuss recent data from the previously completed SIMPLIFY-1 and SIMPLIFY-2 studies presented at this year’s European Hematology Association (EHA) and American Society of Clinical Oncology (ASCO) Annual Meetings. Management will be joined by three Key Opinion Leaders (KOLs) – Aaron Gerds, M.D. (Cleveland Clinic),…

Read More

BeyondSprings Pharma R&D Day: Novel Immune Agent Plinabulin’s Development Program in Anti-cancer Indications

June 23, 2021

The webinar will feature presentations by Key Opinion Leaders (KOLs) Steven Lin, M.D. (MD Anderson Cancer Center), and Trevor M. Feinstein, M.D. (Piedmont Cancer Institute), who will discuss the current treatment landscape and unmet medical need in treating patients with non-small cell lung cancer (NSCLC), and patients who failed checkpoint inhibitors. Drs. Lin and Feinstein…

Read More

Taysha Gene Therapies R&D Day 1

June 23, 2021

Topics of discussion will include: -TSHA-120 (GAN): Pivotal-stage AAV9 gene replacement therapy program for the treatment of giant axonal neuropathy (GAN), a rare autosomal recessive disease of the central and peripheral nervous systems caused by loss-of-function gigaxonin gene mutations. -TSHA-101 (GM2 gangliosidosis): The first bicistronic AAV9 gene therapy in clinical development designed to deliver two…

Read More

Taysha Gene Therapies R&D Day 2

June 23, 2021

Topics of discussion will include: -TSHA-104 (SURF1-associated Leigh syndrome): AAV9-based gene therapy with a transgene encoding the human SURF1 protein to potentially treat SURF1-associated Leigh syndrome, a monogenic mitochondrial disorder with no approved treatments. This gene replacement therapy program is currently in IND/CTA-enabling studies, with an IND/CTA filing expected in the second half of 2021.…

Read More

Scynexis BREXAFEMME® (ibrexafungerp tablets) Commercial Launch Update

June 23, 2021

The event will feature presentations by the SCYNEXIS management team who will discuss its H2:2021 commercial launch plans for BREXAFEMME® (ibrexafungerp tablet), the first approved drug from a novel antifungal class in over 20 years. Also featured will be Key Opinion Leader Michael L. Krychman, M.D.C.M. (Southern California Center for Sexual Health and Survivorship Medicine),…

Read More

Corsair Pharma, Inc KOL Webinar on the Treatment of Pulmonary Arterial Hypertension

June 23, 2021

The webinar will feature a presentation by Key Opinion Leaders (KOLs) Jeremy Feldman, M.D. (Arizona Pulmonary Specialists) and Richard N. Channick, M.D. (David Geffen School of Medicine at UCLA) who will discuss the current treatment landscape and unmet medical need in treating patients with Pulmonary Arterial Hypertension (PAH). Drs. Feldman and Channick will both be…

Read More

Clene Inc. Expert Perspectives Webinar on Cellular Energetic Failure: Addressing Unmet Needs and a New Investigational Treatment for ALS and MS

June 23, 2021

The webinar will feature presentations by two experts: Professor of Neurology Matthew Kiernan, PhD, DSc, FRACP, FAHMS, AM, MBBS and Professor of Neurology Benjamin Greenberg, MD, MHS, FANA, FAAN, CRND, who will discuss the current treatment landscape and unmet medical needs in amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). Following the experts’ presentations, Clene’s…

Read More

Sequana Medical KOL Webinar on the impact of Refractory or Recurrent Liver Ascites on Patients and Healthcare systems and the potential for alfapump® therapy in NASH-related Ascites

June 23, 2021

The webinar will feature: -Testimonial from a patient living with refractory ascites -Presentations by Key Opinion Leaders (KOLs) Hugo E. Vargas, M.D. (Mayo Clinic) and Grace Knuttinen, M.D., Ph.D. (Mayo Clinic), who will discuss the impact of ascites on patients’ quality of life and the limitations of current treatment options. They will also share their…

Read More

Cortexyme KOL Webinar Series on Atuzaginstat:Part 1: Innovation in Periodontal Disease – A Major Unmet Medical Need

June 23, 2021

The webinar will feature a presentation by Key Opinion Leader (KOL) Mark Ryder, M.D. (University of California, San Francisco). On July 23, in conjunction with the International Association for Dental Research (IADR) conference, Cortexyme will present abstract #3571509 entitled “Gingipain Inhibitors Penetrate and Inhibit Gingipains In Porphyromonas gingivalis Biofilms” and abstract #1756 entitled “Novel Lysine-Gingipain…

Read More

Cortexyme KOL Webinar Series on Atuzaginstat: Part 2: Innovation in Alzheimer’s Disease – Getting to the Root Cause of Neurodegeneration

June 23, 2021

The webinar will feature a presentation by Key Opinion Leader (KOL) Marwan Noel Sabbagh, M.D. (Cleveland Clinic). In conjunction with the Alzheimer’s Association International Conference (AAIC) taking place July 26-30, Cortexyme will present an update and baseline data from its Phase 2/3 GAIN Trial of atuzaginstat (COR388), a novel bacterial virulence factor inhibitor for the…

Read More